A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: Meta-analysis

BMJ (Online)

Volumn 338, Issue 7707, 2009, Pages 1371-

  Thaver, Durrane ^a   Zaidi, Anita K M ^a   Critchley, Julia ^b   Azmatullah, Asma ^a   Madni, Syed Ali ^a   Bhutta, Zulfiqar A ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; ENOXACIN; FLEROXACIN; GATIFLOXACIN; LEVOFLOXACIN; NALIDIXIC ACID; OFLOXACIN; PEFLOXACIN; QUINOLONE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; HEALTH CARE QUALITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TYPHOID FEVER;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FLUOROQUINOLONES; HUMANS; INFANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TYPHOID FEVER;

EID: 67650045442     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1865     Document Type: Article

References (87)

1. Crump JA, Luby SP, Mintz ED. Theglobal burden of typhoid fever. Bull World Health Organ 2004;82:346-53.
2. Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, et al. Typhoid fever in children aged less than 5 years. Lancet 1999;354:734-7.
3. Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000;62:644-8.
4. Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T, et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001;20:521-4.
5. Saha MR, Dutta P, Palit A, Dutta D, Bhattacharya MK, Mitra U, et al. A note on incidence of typhoid fever in diverse age groups in Kolkata, India. Jpn J Infect Dis 2003;56:121-2.
6. Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005;11:326-9.
7. Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int J Infect Dis 2006;10:215-2.
8. Sur D, von Seidlein L, Manna B, Dutta S, Deb AK, Sarkar BL, et al. The malaria and typhoid fever burden in the slums of Kolkata, India: data from a prospective community-based study. Trans R Soc Trop Med Hyg 2006;100:725-33.
9. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008;86:260-8.
10. World Health Organization, Department of Vaccines and Biologicals. Treatment of typhoid fever. Background document: the diagnosis, treatment and prevention of typhoid fever. 2003:19-23.
11. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002;347:1770-82.
12. Zaidi AK, Hasan R, Bhutta ZA. Typhoid fever. N Engl J Med 2003;348:1182-4.
13. Brown NM, Millar MR, Frost JA, Rowe B. Ciprofloxacin resistance in Salmonella paratyphi A. J Antimicrob Chemother 1994;33(6):1258-9.
14. Rowe B, Ward LR, Threlfall EJ. Ciprofloxacin-resistant Salmonella typhi in the UK. Lancet 1995;346:1302.
15. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, et al. Quinolone-resistant Salmonella typhi in VietNam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997;25:1404-10.
16. Murdoch DA, Banatvaia N, Bone A, Shoismatulloev BI, Ward LR, Threlfall EJ. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 1998;351:339.
17. Threlfall EJ, Ward LR. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg Infect Dis 2001;7(3):448-50.
18. Asna SM, Haq JA, Rahman MM. Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 2003;56:32-3.
19. Rodrigues C, Shenai S, Mehta A. Enteric fever inMumbai, India: the good news and the bad news. Clin Infect Dis 2003;36:535.
20. Threlfall EJ, Fisher IS, Berghold C, Gerner-Smidt P, Tschape H, Cormican M, et al. Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001. Int J Antimicrob Agents 2003;22:487-91.
21. Parry CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004;98:413-22.
22. Rupali P, Abraham OC, Jesudason MV, John TJ, Zachariah A, Sivaram S, et al. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica Serotype Typhi. Diagn Microbiol Infect Dis 2004;49:1-3.
23. Slinger R, DesjardinsM, McCarthy AE, Ramotar K, Jessamine P, Guibord C, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 2004;:36.
24. Butt T, Ahmad RN, Salman M, Kazmi SY. Changing trends in drug resistance among typhoid salmonellae in Rawalpindi, Pakistan. East Mediterr Health J 2005;11:1038-44.
25. Walia M, Gaind R, Mehta R, Paul P, Aggarwal P, Kalaivani M. Current perspectives of enteric fever: a hospital-based study fromIndia. Ann Trop Paediatr 2005;25:161-74.
26. Butt T, Khan MY, Ahmad RN, Salman M, Afzal RK. Validity of nalidixic acid screening in fluoroquinolone-resistant typhoid salmonellae. J Coll Physicians Surg Pak 2006;16:31-4.
27. Cooke FJ, Wain J, Threlfall EJ. Fluoroquinolone resistance in Salmonella Typhi. BMJ 2006;333:353-4.
28. Maskey AP, Day JN, Phung QT, Thwaites GE, Campbell JI, Zimmerman M, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006;42:1247-53.
29. Mohanty S, Renuka K, Sood S, DAS BK, Kapil A. Antibiogram pattern and seasonality of Salmonella serotypes in a North Indian tertiary care hospital. Epidemiol Infect 2006;134(5):961-966.
30. Chau TT, Campbell JI, Galindo CM, Van Minh HN, Diep TS, Nga TT, et al. Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007;51(12):4315-4323.
31. Dimitrov T, Udo EE, Albaksami O, Kilani AA, Shehab E. Ciprofloxacin treatment failure in a case of typhoid fever caused by Salmonella enterica serotype Paratyphi A with reduced susceptibility to ciprofloxacin. J Med Microbiol 2007;56(Pt 2):277-9.
32. Joshi S, Amarnath SK. Fluoroquinolone resistance in Salmonella typhi and S. paratyphi A in Bangalore, India. Trans R Soc Trop Med Hyg 2007;101:308-10.
33. Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob Agents Chemother 2008;52:1278-84.
34. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 2008;102:91-5.
35. Harish BN, Madhulika U, Parija SC. Isolated high-level ciprofloxacin resistance in Salmonella enterica subspecies enterica serotype Paratyphi A. J Med Microbiol 2004;53:819.
36. Renuka K, Sood S, DAS BK, Kapil A. High-level ciprofloxacin resistance in Salmonella enterica serotype Typhi in India. J Med Microbiol 2005;54:999-1000.
37. Ahmed D, D'Costa LT, Alam K, Nair GB, Hossain MA. Multidrug-resistant Salmonella enterica serovar typhi isolates with high-level resistance to ciprofloxacin in Dhaka, Bangladesh. Antimicrob Agents Chemother 2006;50:3516-7.
38. Harish BN, Menezes GA, Sarangapani K, Parija SC. Fluoroquinolone resistance among Salmonella enterica serovar Paratyphi A in Pondicherry. Indian J Med Res 2006;124:585-7.
39. Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, Zimmerman MD, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS ONE 2007;2:e542.
40. Dolecek C, Tran TP, Nguyen NR, Le TP, Ha V, Phung QT, et al. A multicenter randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS ONE 2008;3:e2188.
41. Turner AK, Nair S, Wain J. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of pointmutations in the topoisomerase targets. J Antimicrob Chemother 2006;58:733-40.
42. Dutta S, Sur D, Manna B, Bhattacharya SK, Deen JL, Clemens JD. Rollback of Salmonella enterica serotype Typhi resistance to chloramphenicol and other antimicrobials in Kolkata, India. Antimicrob Agents Chemother 2005;49:1662-3.
43. Sood S, Kapil A, Das B, Jain Y, Kabra SK. Re-emergence of chloramphenicol-sensitive Salmonella typhi. Lancet 1999;353:1241-2.
44. Takkar VP, Kumar R, Takkar R, Khurana S. Resurgence of chloramphenicol sensitive Salmonella typhi. Indian Pediatr 1995;32:586-7.
45. Wasfy MO, Frenck R, Ismail TF, Mansour H, Malone JL, Mahoney FJ. Trends ofmultiple-drug resistance among Salmonella serotype Typhi isolates during a 14-year period in Egypt. Clin Infect Dis 2002;35:1265-8.
46. Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB. Drug-resistant Salmonella enterica serotype paratyphi A in India. Emerg Infect Dis 2000;6:420-1.
47. Mahmood A. Multidrug resistant Salmonella paratyphi A. J Coll Physicians Surg Pak 2000;10:444.
48. Threlfall EJ, de PE, Day M, Lawrence J, Jones J. Alternatives to ciprofloxacin use for enteric Fever, United kingdom. Emerg Infect Dis 2008;14:860-1.
49. Thaver D, Zaidi AK, Critchley J, Azmatullah A, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2008;(4):CD004530.
50. In: Higgins J, Green S, eds. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. 2006. www.cochrane.org/resources/handbook/hbook.htm (accessed 26 November 2007).
51. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
52. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
53. Alderson P, Green S, eds. Cochrane Collaboration open learning material for reviewers (version 1.1). Cochrane Collaboration, 2002. www.cochrane-net.org/ openlearning/ (accessed 28 Nov 2008).
54. Butler T, Islam A, Kabir I, Jones PK. Patterns ofmorbidity andmortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea. Rev Infect Dis 1991;13:85-90.
55. Mahle WT, Levine MM. Salmonella typhi infection in children younger than five years of age. Pediatr Infect Dis J 1993;12:627-31.
56. Bhutta ZA. Impact of age and drug resistance onmortality in typhoid fever. Arch Dis Child 1996;75:214-7.
57. Walia M, Gaind R, Paul P, Mehta R, Aggarwal P, Kalaivani M. Agerelated clinical and microbiological characteristics of enteric fever in India. Trans R Soc Trop Med Hyg 2006;100:942-8.
58. Gendrel D, Chalumeau M, Moulin F, Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet Infect Dis 2003;3:537-46.
59. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006;118:1287-92.
60. Nalin DR, Hoagland VL, Acuna G, Bran JL, Carrillo C, Gotuzzo E. Clinical trial of norfloxacin versus chloramphenicol therapy for acute typhoid fever. In: Progress in antimicrobial and anti-cancer chemotherapy. Proceedings of the 15th International Congress of Chemotherapy; 1987 July 19-24; Istanbul. Copenhagen, Munksgaard, 1987:1174-5.
61. Sarma PS, Durairaj P. Randomized treatment of patients with typhoid and paratyphoid fevers using norfloxacin or chloramphenicol. Trans R Soc TropMedHyg 1991;85:670-1.
62. Huai Y, Zhu Q,Wang X. Ceftriaxone vs. norfloxacin in the treatment of resistant typhoid fever in 60 children. Zhonghua Er Ke Za Zhi [Chinese Journal of Pediatrics] 2000;38(:386-8.
63. Quintero-Perez NP, Andrade-Villanueva J, Leon-Garnica M, Bertin-Montano M, Rodrigues-Chagollan-E, Rodriguez-Noriega E. Comparative double blind efficacy and safety study of ciprofloxacin with chloramphenicol in the treatment of typhoid fever (Abstract number 385). In: Programs and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1988 Oct 23-26; Los Angeles, California. Washington, DC: American Society for Microbiology, 1988:177.
64. Bran JL, Garcia JF, Mendez O. Comparative, double blind study of chloramphenicol and ciprofloxacin in the treatment of typhoid fever (Abstract number 751). In: Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Sept 29-Oct 2; Chicago, Illinois. Washington, DC: American Society of Microbiology, 1991:224.
65. Gottuzzo E, Carrillo C. Typhoid fever. Evaluation of the efficacy and safety of ciprofloxacin in comparison with chloramphenicol. In: HL Dupont, ed. Use of quinolones in travel medicine. Second Conference on International Travel Medicine, Atlanta, Georgia 1991. Berlin, Germany: Springer-Verlag, 1992:16-22.
66. Morelli G, Mazzoli S, Tortoli E, Simonetti MT, Perruna F, Postiglione A. Fluoroquinolones versus chloramphenicol in the therapy of typhoid fever: a clinical and microbiological study. Current Therapeutic Research 1992;52:532-42.
67. Yousaf MH, Hasnain SS, Mohsin A, Ara N. A comparative study of efficacy and safety of three antimicrobials in the treatment of enteric fever. Pakistan Journal of Gastroenterology 1992;6(:46-8.
68. Abejar NH, Dimaano EM, Cabanban AB. Fleroxacin versus chloramphenicol in enteric fever. An open, randomized, parallel study. Philippine Journal of Internal Medicine 1993;31:327-30.
69. Arnold K, Hong CS, Nelwan R, Zavala-Trujillo I, Kadio A, Barros MA, et al. Randomized comparative study of fleroxacin and chloramphenicol in typhoid fever. Am J Med 1993;94:195S-200S.
70. Cristiano P, Imparato L, Carpinelli C, Lauria F, Iovene MR, Corrado MF, et al. Pefloxacin versus chloramphenicol in the therapy of typhoid fever. Infection 1995;23:103-6.
71. Gasem MH, Keuter M, Dolmans WM, Van Der Ven-Jongekrijg J, Djokomoeljanto R, Van Der Meer JW. Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. Antimicrob Agents Chemother 2003;47(:1727-31.
72. Phongmany S, Phetsouvanh R, Sisouphone S, Darasavath C, Vongphachane P, Rattanavong O, et al. A randomized comparison of oral chloramphenicol versus ofloxacin in the treatment of uncomplicated typhoid fever in Laos. Trans R Soc Trop Med Hyg 2005;99:451-8.
73. Wallace MR, Yousif AA, Mahroos GA, Mapes T, Threlfall EJ, Rowe B, et al. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 1993;12:907-10.
74. Smith MD, Duong NM, Hoa NT, Wain J, Ha HD, Diep TS, et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994;38:1716-20.
75. Tran TH, Nguyen MD, Huynh DH, Nguyen TT, To SD, Le TP, et al. A randomized comparative study of fleroxacin and ceftriaxone in enteric fever. Trans R Soc Trop Med Hyg 1994;88:464-5.
76. Yu Y-S, Zheng J-C, Gan M-J, Ma Y-L. Clinical study on the efficacy and safety of the levofloxacin used to treat the patientswith typhoid fever or paratyphoid fever. Zhongguo Lin Chuang Yao Li Xue Za Zhi [Chinese Journal of Clinical Pharmacology] 1998;14:70-4.
77. Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, Parry CM. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr Infect Dis J 1999;18:245-8.
78. Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, Tribble D, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999;43:1441-4.
79. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 2000;44:1855-9.
80. Parry CM, Ho VA, Phuong lT, Bay PV, Lanh MN, Tung lT, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrugresistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 2007;51:819-25.
81. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5.
82. Acharya G, Butler T, Ho M, Sharma PR, Tiwari M, Adhikari RK, et al. Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol. Am J Trop Med Hyg 1995;52:162-5.
83. Bhutta ZA, Khan IA, Shadmani M. Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother 2000;44:450-2.
84. Islam A, Butler T, Nath SK, Alam NH, Stoeckel K, Houser HB, et al. Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol. J Infect Dis 1988;158:742-7.
85. Lasserre R, Sangalang RP, Santiago L. Three-day treatment of typhoid fever with two different doses of ceftriaxone, compared to 14-day therapy with chloramphenicol: a randomized trial. J Antimicrob Chemother 1991;28:765-72.
86. Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. BMJ 2006;333:78-82.
87. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol Infect 2008;136:436-48.